Kim, S. et al. Chemical structure and biological activities of secondary metabolites from salicornia Europaea L. Molecules 26 (8), 2252 (2021).
Kwon, B. S. et al. Chronic alcohol exposure induced neuroapoptosis: diminishing effect of Ethyl acetate fraction from Aralia Elata. Oxidative Med. Cell. Longev. 2019 (1), 7849876 (2019).
Yuan, C. et al. Chikusetsu saponin IVa ameliorates high fat diet-induced inflammation in adipose tissue of mice through Inhibition of NLRP3 inflammasome activation and NF-κB signaling. Oncotarget 8 (19), 31023 (2017).
Fang, X. et al. Chikusetsu saponin IVa attenuates isoflurane-induced neurotoxicity and cognitive deficits via SIRT1/ERK1/2 in developmental rats. Am. J. Translational Res. 9 (9), 4288 (2017).
Xin, Y. et al. MiR-155/GSK-3β mediates anti-inflammatory effect of Chikusetsusaponin IVa by inhibiting NF-κB signaling pathway in LPS-induced RAW264. 7 cell. Sci. Rep. 10 (1), 18303 (2020).
Wang, X. et al. Panax japonicus and chikusetsusaponins: A review of diverse biological activities and Pharmacology mechanism. Chin. Herb. Med. 13 (1), 64–77 (2021).
Gao, K. et al. Chikusetsusaponin IVa targeted YAP as an inhibitor to attenuate liver fibrosis and hepatic stellate cell activation. Chin. Med. 20 (1), 36 (2025).
Guo, X. et al. Anti-inflammatory and osteoprotective effects of Chikusetsusaponin Ⅳa on rheumatoid arthritis via the JAK/STAT signaling pathway. Phytomedicine 93, 153801 (2021).
Dai, Q. et al. Chikusetsusaponin IVa protects against H9N2 avian influenza virus infection by inhibiting inflammation and TLR4/NF-κB signaling pathways in vitro and in vivo. Pharmacognosy Magazine. 20 (2), 632–645 (2024).
Zeng, Q. et al. Anti-inflammatory mechanism of Achyranthes longifolia extract and its component chikusetsusaponin IVa by modulating Nrf2/NF-κB pathways in vitro and in vivo. Fitoterapia. 106593 (2025).
Patra, J. K. et al. Nano based drug delivery systems: recent developments and future prospects. J. Nanobiotechnol. 16 (1), 71 (2018).
Haggag, Y. A. et al. Nano-encapsulation of a novel anti-Ran-GTPase peptide for Blockade of regulator of chromosome condensation 1 (RCC1) function in MDA-MB-231 breast cancer cells. Int. J. Pharm. 521 (1–2), 40–53 (2017).
Haggag, Y. et al. Co-delivery of a RanGTP inhibitory peptide and doxorubicin using dual-loaded liposomal carriers to combat chemotherapeutic resistance in breast cancer cells. Expert Opin. Drug Deliv. 17 (11), 1655–1669 (2020).
Zewail, M. B. et al. Preparation and in vitro characterization of a novel self-nano emulsifying drug delivery system for a fixed-dose combination of Candesartan cilexetil and Hydrochlorothiazide. J. Drug Deliv. Sci. Technol. 61, 102320 (2021).
Jan, N. et al. Biomimetic cell membrane-coated Poly (lactic‐co‐glycolic acid) nanoparticles for biomedical applications. Bioeng. Translational Med. 8 (2), e10441 (2023).
Mahar, R. et al. Application of PLGA as a biodegradable and biocompatible polymer for pulmonary delivery of drugs. Aaps Pharmscitech. 24 (1), 39 (2023).
Singh, S. & Singha, P. Effect of modifications in Poly (lactide-co-glycolide)(PLGA) on drug release and degradation characteristics: a mini review. Curr. Drug Deliv. 18 (10), 1378–1390 (2021).
Care, I. O. L. A. & Animals, U. O. L. Guide for the Care and Use of Laboratory Animals (US Department of Health and Human Services, Public Health Service, National (1986).
Si, W. et al. Toward Understanding the effect of solvent evaporation on the morphology of PLGA microspheres by double emulsion method. Ind. Eng. Chem. Res. 60 (25), 9196–9205 (2021).
Mittal, P. et al. Formulation, optimization, hemocompatibility and Pharmacokinetic evaluation of PLGA nanoparticles containing Paclitaxel. Drug Dev. Ind. Pharm. 45 (3), 365–378 (2019).
Qi, D. et al. Determination of Chikusetsusaponin V and Chikusetsusaponin IV in rat plasma by liquid chromatography–mass spectrometry and its application to a preliminary Pharmacokinetic study. Biomed. Chromatogr. 27 (11), 1568–1573 (2013).
Li, W. et al. Puerarin-loaded PEG-PE micelles with enhanced anti-apoptotic effect and better Pharmacokinetic profile. Drug Deliv. 25 (1), 827–837 (2018).
Wang, Y. et al. Determination and validation of Chikusetsusaponin IVa in rat plasma by UPLC-MS/MS and its application to Pharmacokinetic study. Biomed. Chromatogr. 30 (9), 1423–1429 (2016).
Li, H. et al. The effects of Chuanxiong on the pharmacokinetics of warfarin in rats after biliary drainage. J. Ethnopharmacol. 193, 117–124 (2016).
Zhang, Y. et al. Pharmacokinetic profiling and tissue distribution of seven key saponins in rats following oral administration of Panacis Japonici rhizoma extracts. ACS Omega. 10 (38), 44585–44595 (2025).
Constantinides, C. & Murphy, K. Molecular and integrative physiological effects of isoflurane anesthesia: the paradigm of cardiovascular studies in rodents using magnetic resonance imaging. Front. Cardiovasc. Med. 3, 23 (2016).
Lepoittevin, M. et al. Comparison between 5 extractions methods in either plasma or serum to determine the optimal extraction and matrix combination for human metabolomics. Cell. Mol. Biol. Lett. 28 (1), 43 (2023).
Cardot, J. & Davit, B. M. vitro–in vivo correlations: tricks and traps. AAPS J. 14 (3), 491–499 (2012).
Haggag, Y. A. et al. Effect of Poly (ethylene glycol) content and formulation parameters on particulate properties and intraperitoneal delivery of insulin from PLGA nanoparticles prepared using the double-emulsion evaporation procedure. Pharm. Dev. Technol. 23 (4), 370–381 (2018).
Haggag, Y. et al. Preparation and in vivo evaluation of insulin-loaded biodegradable nanoparticles prepared from Diblock copolymers of PLGA and PEG. Int. J. Pharm. 499 (1–2), 236–246 (2016).
Alvi, M. et al. PLGA-based nanoparticles for the treatment of cancer: current strategies and perspectives. AAPS Open. 8 (1), 12 (2022).
Jusu, S. M. et al. Drug-encapsulated blend of PLGA-PEG microspheres: in vitro and in vivo study of the effects of localized/targeted drug delivery on the treatment of triple-negative breast cancer. Sci. Rep. 10 (1), 14188 (2020).
Gupta, V. & Ahsan, F. Influence of PEI as a core modifying agent on PLGA microspheres of PGE1, a pulmonary selective vasodilator. Int. J. Pharm. 413 (1–2), 51–62 (2011).
Yu, K. et al. Enhanced delivery of Paclitaxel using electrostatically-conjugated Herceptin-bearing PEI/PLGA nanoparticles against HER-positive breast cancer cells. Int. J. Pharm. 497 (1–2), 78–87 (2016).
Kaplan, M. et al. Effects of particle geometry for PLGA-based nanoparticles: Preparation and in vitro/in vivo evaluation. Pharmaceutics 15 (1), 175 (2023).
Xu, Y. et al. Polymer degradation and drug delivery in PLGA-based drug–polymer applications: A review of experiments and theories. J. Biomedical Mater. Res. part. B: Appl. Biomaterials. 105 (6), 1692–1716 (2017).
Zhao, C. & Zhou, B. Polyethyleneimine-based drug delivery systems for cancer theranostics. J. Funct. Biomaterials. 14 (1), 12 (2022).
Balusamy, S. R. et al. A comprehensive and systemic review of ginseng-based nanomaterials: Synthesis, targeted delivery, and biomedical applications. Med. Res. Rev. 43 (5), 1374–1410 (2023).
Shahbaz, S. K. et al. PLGA-based Curcumin delivery system: an interesting therapeutic approach in the treatment of alzheimer’s disease. Curr. Neuropharmacol. 20 (2), 309–323 (2022).
Gupta, R., Chen, Y. & Xie, H. In vitro dissolution considerations associated with nano drug delivery systems. Wiley Interdisciplinary Reviews: Nanomed. Nanobiotechnol. 13 (6), e1732 (2021).
Lindsay, S. et al. Exploring the challenges of lipid nanoparticle development: the in vitro–in vivo correlation gap. Vaccines 13 (4), 339 (2025).
Lou, Y. et al. Effects of the CYP3A inhibitors, voriconazole, itraconazole, and fluconazole on the pharmacokinetics of osimertinib in rats[J]. PeerJ 11, e15844 (2023).
